Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05181748
PHASE2/PHASE3

Autologous Platelet Rich Plasma Intraovarian Infusion for Poor Responders

Sponsor: Genesis Athens Clinic

View on ClinicalTrials.gov

Summary

Autologous platelet rich plasma (PRP) intraovarian infusion may improve ovarian response to controlled ovarian stimulation as well as the hormonal profile of poor ovarian response infertile women subjected to intracytoplasmic sperm injection (ICSI) treatment.

Official title: Investigating the Efficiency of Autologous Platelet Rich Plasma Intraovarian Infusion on Improving Ovarian Functionality in Poor Ovarian Response Patients

Key Details

Gender

FEMALE

Age Range

35 Years - 47 Years

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2019-01-23

Completion Date

2026-01-31

Last Updated

2024-12-27

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

Autologous platelet rich plasma

Preparation of PRP will be performed immediately following blood sample collection. Blood samples will be collected from the median antebrachial vein. PRP will be prepared according to the manufacturer's instructions employing a Regen Autologous Cellular Regeneration (ACR®-C) Kit (Regen Laboratory, Le Mont-sur-Lausanne, Switzerland). Approximately 60 mL of the patient's peripheral blood will be required in order to yield the required volume of PRP. The goal concentration of platelets in PRP is approximately 1.000.000 platelets/µL. The technique of PRP intraovarian infusion resembles the transvaginal paracentesis performed during the oocyte pick-up procedure. Briefly, both ovaries are visualized via transvaginal ultrasound monitoring, and they are intramedullary injected on multiple sites using a 17-gauge single lumen needle, with the patient under inhaled minimal sedation.

Locations (1)

Genesis Athens Clinic

Athens, Attica, Greece